Keros Therapeutics Inc
Research Keros Therapeutics Inc (KROS) on Bullrun: market cap USD 216.32M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerKROS
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 216.32M
- Financial periodFY2025
- RevenueUSD 244.06M
- Revenue growth6775.0%
- Net incomeUSD 87.01M
- Free cash flowUSD 105.95M
Valuation Snapshot
latest market cap is USD 216.32M.
About Keros Therapeutics Inc
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. It develops rinvatercept, which acts as a ligand trap and inhibits the biological effects of myostatin and activin A in Phase 1 clinical trials for Duchenne Muscular Dystrophy and Amyotrophic Lateral Sclerosis;
Frequently asked questions
What is Keros Therapeutics Inc's market cap?
Keros Therapeutics Inc's market capitalization is USD 216.32M.
What does Keros Therapeutics Inc do?
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States.